6 alpha mercaptopurine sensitivity

6-Alpha-Mercaptopurine Sensitivity is a condition related to the adverse reactions experienced by individuals when exposed to 6-alpha-mercaptopurine (6-MP), a medication primarily used in the treatment of leukemia and certain autoimmune diseases. This sensitivity can manifest in various forms, ranging from mild to severe side effects, depending on the individual's genetic makeup and their ability to metabolize the drug.

Overview[edit | edit source]

6-Alpha-Mercaptopurine is a purine analogue that interferes with the synthesis of DNA and RNA, making it effective in the treatment of diseases characterized by rapid cell division. However, its efficacy and safety profile can be significantly affected by individual variations in drug metabolism, leading to sensitivity in some patients.

Causes[edit | edit source]

The primary cause of 6-alpha-mercaptopurine sensitivity is genetic variations in the TPMT (thiopurine S-methyltransferase) enzyme, which is crucial for the metabolism of thiopurine drugs like 6-MP. Individuals with reduced or absent TPMT activity are at a higher risk of developing toxicity from standard doses of 6-MP due to the accumulation of active metabolites.

Symptoms[edit | edit source]

Symptoms of 6-alpha-mercaptopurine sensitivity can include:

Myelosuppression (reduced bone marrow activity)
Hepatotoxicity (liver damage)
Pancreatitis (inflammation of the pancreas)
Nausea and vomiting
Rash and other allergic reactions

Diagnosis[edit | edit source]

Diagnosis of 6-alpha-mercaptopurine sensitivity involves genetic testing to assess TPMT enzyme activity levels. This testing can help identify individuals at risk of toxicity before initiating treatment with 6-MP.

Treatment[edit | edit source]

Management of 6-alpha-mercaptopurine sensitivity primarily involves adjusting the dose of 6-MP based on TPMT activity or considering alternative medications. In cases of severe toxicity, discontinuation of the drug may be necessary.

Prevention[edit | edit source]

Preventive measures include genetic screening for TPMT activity in patients who are candidates for 6-MP therapy. This approach allows for personalized medicine, where drug doses are tailored to the individual's genetic profile to minimize the risk of adverse effects.